Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03905148 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
A Phase 1 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
NCT03905148 is a Phase 1 study that has completed, run by BeiGene. The registered enrollment target is 91 participants.
The verdict
NCT03905148, a Phase 1 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
Study Summary
This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.
Interventions
- DRUG Lifirafenib
- DRUG mirdametinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2025-10-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03905148
The ClinicalTrials.gov registry entry for NCT03905148 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lifirafenib is the first listed.
NCT03905148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03905148 about?
NCT03905148 is a clinical study titled "Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors". This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.
What is the current status of trial NCT03905148?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2019-05-01. Estimated completion is 2025-10-23.
What interventions are being tested in trial NCT03905148?
The interventions under investigation include: Lifirafenib (DRUG), mirdametinib (DRUG).
Who is sponsoring clinical trial NCT03905148?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.